304 related articles for article (PubMed ID: 23358420)
1. Large FK506-binding proteins shape the pharmacology of rapamycin.
März AM; Fabian AK; Kozany C; Bracher A; Hausch F
Mol Cell Biol; 2013 Apr; 33(7):1357-67. PubMed ID: 23358420
[TBL] [Abstract][Full Text] [Related]
2. FKBPs and the Akt/mTOR pathway.
Hausch F; Kozany C; Theodoropoulou M; Fabian AK
Cell Cycle; 2013 Aug; 12(15):2366-70. PubMed ID: 23839048
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins.
Schreiber KH; Ortiz D; Academia EC; Anies AC; Liao CY; Kennedy BK
Aging Cell; 2015 Apr; 14(2):265-73. PubMed ID: 25652038
[TBL] [Abstract][Full Text] [Related]
4. Antascomicin B stabilizes FKBP51-Akt1 complexes as a molecular glue.
Schäfer SC; Voll AM; Bracher A; Ley SV; Hausch F
Bioorg Med Chem Lett; 2024 May; 104():129728. PubMed ID: 38582133
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways Leading to Induction of Cell Death and Anti-Proliferative Properties by Tacrolimus and mTOR Inhibitors in Liver Cancer Cells.
Navarro-Villarán E; de la Cruz-Ojeda P; Contreras L; González R; Negrete M; Rodríguez-Hernández MA; Marín-Gómez LM; Álamo-Martínez JM; Calvo A; Gómez-Bravo MA; de la Cruz J; Padillo J; Muntané J
Cell Physiol Biochem; 2020 May; 54(3):457-473. PubMed ID: 32369692
[TBL] [Abstract][Full Text] [Related]
6. FK506 binding proteins as targets in anticancer therapy.
Romano S; Di Pace A; Sorrentino A; Bisogni R; Sivero L; Romano MF
Anticancer Agents Med Chem; 2010 Nov; 10(9):651-6. PubMed ID: 21182472
[TBL] [Abstract][Full Text] [Related]
7. FK506 binding protein 12 mediates sensitivity to both FK506 and rapamycin in murine mast cells.
Fruman DA; Wood MA; Gjertson CK; Katz HR; Burakoff SJ; Bierer BE
Eur J Immunol; 1995 Feb; 25(2):563-71. PubMed ID: 7533090
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins.
Weiwad M; Edlich F; Kilka S; Erdmann F; Jarczowski F; Dorn M; Moutty MC; Fischer G
Biochemistry; 2006 Dec; 45(51):15776-84. PubMed ID: 17176100
[TBL] [Abstract][Full Text] [Related]
9. FK506 binding proteins and inflammation related signalling pathways; basic biology, current status and future prospects for pharmacological intervention.
Annett S; Moore G; Robson T
Pharmacol Ther; 2020 Nov; 215():107623. PubMed ID: 32622856
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the FKBP.rapamycin.FRB ternary complex.
Banaszynski LA; Liu CW; Wandless TJ
J Am Chem Soc; 2005 Apr; 127(13):4715-21. PubMed ID: 15796538
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin exerts antifungal activity in vitro and in vivo against Mucor circinelloides via FKBP12-dependent inhibition of Tor.
Bastidas RJ; Shertz CA; Lee SC; Heitman J; Cardenas ME
Eukaryot Cell; 2012 Mar; 11(3):270-81. PubMed ID: 22210828
[TBL] [Abstract][Full Text] [Related]
12. Multi-timescale dynamics study of FKBP12 along the rapamycin-mTOR binding coordinate.
Sapienza PJ; Mauldin RV; Lee AL
J Mol Biol; 2011 Jan; 405(2):378-94. PubMed ID: 21073880
[TBL] [Abstract][Full Text] [Related]
13. Calcium- and FK506-independent interaction between the immunophilin FKBP51 and calcineurin.
Li TK; Baksh S; Cristillo AD; Bierer BE
J Cell Biochem; 2002; 84(3):460-71. PubMed ID: 11813252
[TBL] [Abstract][Full Text] [Related]
14. Regulation by FK506 and rapamycin of Ca2+ release from the sarcoplasmic reticulum in vascular smooth muscle: the role of FK506 binding proteins and mTOR.
MacMillan D; McCarron JG
Br J Pharmacol; 2009 Oct; 158(4):1112-20. PubMed ID: 19785652
[TBL] [Abstract][Full Text] [Related]
15. Secretion of FK506/FK520 and rapamycin by Streptomyces inhibits the growth of competing Saccharomyces cerevisiae and Cryptococcus neoformans.
Arndt C; Cruz MC; Cardenas ME; Heitman J
Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():1989-2000. PubMed ID: 10463165
[TBL] [Abstract][Full Text] [Related]
16. FKBP12 is the only FK506 binding protein mediating T-cell inhibition by the immunosuppressant FK506.
Xu X; Su B; Barndt RJ; Chen H; Xin H; Yan G; Chen L; Cheng D; Heitman J; Zhuang Y; Fleischer S; Shou W
Transplantation; 2002 Jun; 73(11):1835-8. PubMed ID: 12085010
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin-inspired macrocycles with new target specificity.
Guo Z; Hong SY; Wang J; Rehan S; Liu W; Peng H; Das M; Li W; Bhat S; Peiffer B; Ullman BR; Tse CM; Tarmakova Z; Schiene-Fischer C; Fischer G; Coe I; Paavilainen VO; Sun Z; Liu JO
Nat Chem; 2019 Mar; 11(3):254-263. PubMed ID: 30532015
[TBL] [Abstract][Full Text] [Related]
18. The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis.
Krummrei U; Baulieu EE; Chambraud B
Proc Natl Acad Sci U S A; 2003 Mar; 100(5):2444-9. PubMed ID: 12604780
[TBL] [Abstract][Full Text] [Related]
19. InterAKTions with FKBPs--mutational and pharmacological exploration.
Fabian AK; März A; Neimanis S; Biondi RM; Kozany C; Hausch F
PLoS One; 2013; 8(2):e57508. PubMed ID: 23469007
[TBL] [Abstract][Full Text] [Related]
20. FKBP51 regulation of AKT/protein kinase B phosphorylation.
Wang L
Curr Opin Pharmacol; 2011 Aug; 11(4):360-4. PubMed ID: 21498116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
